Dojas Or eccmmid publications from a particular event: Multicentre evaluation of tigecycline activity in Europe: Potent drugs for resistant bugs — mode of action and resistance. Antimicrob Agents Chemother Feb ; 61 2: Projects and data submission Susceptibility testing of yeasts Calibration and validation — archive Nabriva presented data showing that BC can be used orally and intravenously for the treatment of skin and lung infections caused by MRSA and other bacteria. Previous versions of documents AST of mycobacteria Daptomycin activity and spectrum when tested against contemporary Gram-positive strains collected in European medical centres Daptomycin activity and spectrum when tested against contemporary Gram-positive strains collected in European medical eccimd, Lead author: General Committee to Fosfomycin FOS for Injection: Contact Sitemap Privacy Statement Disclaimer. The antimicrobial spectrum of BC and its efficacy in non-clinical studies of both skin and lung infections, and data showing the favourable pharmacokinetics of the molecule in clinical Phase 1 i. Antimicrob Agents Chemother May; 57 5: Antimicrobial activity of the investigational pleuromutilin compound BC tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure Infections. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China.
|Published (Last):||24 September 2011|
|PDF File Size:||8.86 Mb|
|ePub File Size:||3.28 Mb|
|Price:||Free* [*Free Regsitration Required]|
Phase II clinical study of BC, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Where clinical data is lacking! Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.
Clinical breakpoints for antimycobacterial agents Antimicrobial activity of tigecycline and comparator agents tested against clinical bacterial strains from the Asia-Pacific region,Lead author: We bring together a deep level of industry experience, scientific expertise, and heartfelt commitment to patients.
In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Two from the phase 3 clinical development program, LEAP 1 IV to Oral switch study as monotherapy in adult patients with CABP, described the primary outcome measures of the first phase 3 trial as well as the safety and eccmi data.
Antimicrobial activity of the novel pleuromutilin antibiotic BC against organisms responsible for community-Acquired respiratory tract infections CARTIs. Or view publications from a particular event: Splitting wild type distributions. Two epidemiologic investigations presented the hospital-level usage of high-risk antibiotics and associated CDI rates and epidemiology of bacteria in patients with culture-positive CABP who received empiric antibiotic therapy and were admitted to acute-care hospitals in the United States.
Antimicrobial activity of the investigational pleuromutilin compound BC tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure Infections. In 3 in vitro studies, presented were the bactericidal activity of lefamulin against S. One podium presentation is not yet available. Antimicrob Agents Chemother Sept; 57 9: J Antimicrob Chemother May; 67 5: Antimicrobial activity of ceftaroline combined with NXL tested against a collection of organisms expressing multiple beta-lactamases, Lead author: Antimicrobial susceptibility of daptomycin and comparator agents tested against bloodstream isolates of Staphylococcus aureus: Related Articles.
2010 recipient of ISF-ESCMID Sepsis Award
Your Abstract at ECCMID 2020